Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

405 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer.
Andreis D, Bonardi S, Allevi G, Aguggini S, Gussago F, Milani M, Strina C, Spada D, Ferrero G, Ungari M, Rocca A, Nanni O, Roviello G, Berruti A, Harris AL, Fox SB, Roviello F, Polom K, Bottini A, Generali D. Andreis D, et al. Among authors: ferrero g. Breast. 2016 Oct;29:55-61. doi: 10.1016/j.breast.2016.07.003. Epub 2016 Jul 16. Breast. 2016. PMID: 27428471
Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy".
Foroni C, Milan M, Strina C, Cappelletti M, Fumarola C, Bonelli M, Bertoni R, Ferrero G, Maldotti M, Takano E, Andreis D, Venturini S, Brugnoli G, Petronini PG, Zanoni V, Pritzker L, Pritzker K, Parissenti A, Santini D, Fox SB, Bottini A, Generali D. Foroni C, et al. Among authors: ferrero g. Breast Cancer Res Treat. 2014 Feb;144(1):113-21. doi: 10.1007/s10549-014-2840-y. Epub 2014 Jan 28. Breast Cancer Res Treat. 2014. PMID: 24469643 Clinical Trial.
Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy.
Koukourakis MI, Giatromanolaki A, Bottini A, Cappelletti MR, Zanotti L, Allevi G, Strina C, Ardine M, Milani M, Brugnoli G, Martinotti M, Ferrero G, Bertoni R, Ferrozzi F, Harris AL, Generali D. Koukourakis MI, et al. Among authors: ferrero g. Br J Cancer. 2014 Apr 29;110(9):2209-16. doi: 10.1038/bjc.2014.196. Epub 2014 Apr 10. Br J Cancer. 2014. PMID: 24722179 Free PMC article.
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
Generali D, Buffa FM, Deb S, Cummings M, Reid LE, Taylor M, Andreis D, Allevi G, Ferrero G, Byrne D, Martinotti M, Bottini A, Harris AL, Lakhani SR, Fox SB. Generali D, et al. Among authors: ferrero g. Br J Cancer. 2014 Jul 8;111(1):46-54. doi: 10.1038/bjc.2014.236. Epub 2014 May 29. Br J Cancer. 2014. PMID: 24874483 Free PMC article. Clinical Trial.
Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1α and Relation to Clinical Response.
Generali D, Berruti A, Cappelletti MR, Zanotti L, Brugnoli G, Forti M, Bedussi F, Vailati ME, Milani M, Strina C, Ardine M, Aguggini S, Allevi G, Ferrero G, Bertoni R, Bottini A, Harris AL, Fox SB. Generali D, et al. Among authors: ferrero g. J Natl Cancer Inst Monogr. 2015 May;2015(51):64-6. doi: 10.1093/jncimonographs/lgv018. J Natl Cancer Inst Monogr. 2015. PMID: 26063890 Clinical Trial.
Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature.
Bernocchi O, Sirico M, Corona SP, Strina C, Milani M, Cappelletti MR, Ferrero G, Ziglioli N, Cervoni V, Macchiavelli A, Roviello G, Generali D. Bernocchi O, et al. Among authors: ferrero g. Pharmaceuticals (Basel). 2021 Feb 16;14(2):159. doi: 10.3390/ph14020159. Pharmaceuticals (Basel). 2021. PMID: 33669326 Free PMC article.
405 results